This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Elan and Wyeth Had Ties to Study's Authors

Updated from 6:59 a.m. EDT

An Alzheimer's disease research paper published last year in a prestigious medical journal failed to disclose the financial ties one of the co-authors had to Elan (ELN) and Wyeth (WYE) as a paid consultant to the drugmakers.

The paper in the September 2007 Archives of Neurology, a journal published by the American Medical Association, describes the use of a new test -- the neuropsychological test battery (NTB) -- to measure the memory and mental status of patients with Alzheimer's disease.

John Harrison, the consultant, was paid by Elan and Wyeth to create the NTB as a new cognitive test for the company's experimental Alzheimer's drug, bapineuzumab. As previously reported by, Elan and Wyeth are seeking to convince regulators here and in Europe that the NTB should be used as the basis to approve bapineuzumab.

The NTB, the companies have argued, is a superior alternative to the ADAS-cog test, the most well-known and widely used measure of cognition in studies of mild to moderate Alzheimer's patients today.

To help make their point, Elan and Wyeth have cited the Archives of Neurology paper, titled "A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials," as independent, scientific proof that validates the NTB.

Harrison is the lead author of that NTB paper, but his role as a consultant paid by Elan and Wyeth to create the test is not disclosed in it. Harrison is the only author of six listed in the paper's conflict-of-interest statement as having no financial conflicts with Elan and Wyeth. Harrison's five co-authors are all employed by Elan or Wyeth.

"The drafts of our manuscript specifically included reference to the fact that I had received payment from both Elan and Wyeth, though for some reason this disclosure does not appear in the published manuscript," said Harrison in an email response to questions.

"This is clearly worthy of further investigation, and I will seek to discover why this statement was omitted," he added.

Why Does Full Disclose Matter?

Studies have shown that when drug companies or an industry fund scientific research, the conclusions of that research tend to favor those who pay for it. This is why independent research is so highly valued and why, when drug companies are involved in the conduct or payment of research, proper financial disclosure is necessary.

One of the criticisms of Elan and Wyeth's efforts to push the NTB as a new approval standard for Alzheimer's drugs is that the two companies created the test specifically for use with their experimental drug bapineuzumab.

While the NTB is made up of component tests of memory and executive function that have been commonly used for years, the precise selection of certain tests, the omission of others and their compilation into a single battery with a specific statistical scoring system were all done with bapineuzumab in mind.

Elan and Wyeth, therefore, have financial involvement not only in developing a new Alzheimer's drug, bapineuzumab, but also in the NTB test being used to evaluate bapineuzumab and in the research study published in the Archives of Neurology that purports to show that the NTB test is better than the ADAS-cog.

By comparison, the ADAS-cog test has been used successfully to get Alzheimer's drugs approved, because it has been widely validated through years of independent research and use in clinical studies worldwide for a host of different drugs.

An Elan spokesman was asked to provide all independent research that validates the use of the NTB in Alzheimer's clinical trials, especially since the NTB has never before been used as the basis to approve an Alzheimer's drug.

The only research cited by the Elan spokesman, however, was the Archives of Neurology paper, which concludes, "The NTB ... seems to be a reliable and sensitive measure of cognitive change in patients with mild to moderate Alzheimer disease. The psychometric properties of the NTB suggest that it may have particular utility in evaluating drug efficacy in clinical trials in which patients with mild Alzheimer disease are included."

The authors of this paper, and that includes Harrison, all have financial ties to Elan and Wyeth.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
JNJ $101.82 0.00%
LLY $71.27 0.00%
MRK $49.03 0.00%
NVS $72.70 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs